With their new name to reflect the journey their patients undergo when treated with psychedelic drugs, Tryptamine Therapeutics (ASX: TYP) has confirmed that all patients suffering from fibromyalgia that took their TRP-8802 drug, an oral psilocybin formulation, demonstrated significant pain relief. The study, conducted in collaboration with the University of Michigan (UOM), was presented at
Read More
In a world where craft beverages are celebrated for their diversified tastes, beer remains a timeless favorite. Despite a challenging economic landscape, independent beverage company Good Drinks Australia (ASX: GDA), is brewing a positive financial performance. GDA’s financial growth is experiencing a spike, attributed to its own brand volumes and key strategic initiatives that include
Read More
The XJO is expected to open flat this morning following a subdued night of trading in the U.S. Their futures are also flat. After a strong run higher from our lows, it makes sense to see markets pause for the moment. Especially considering we have paused at the 50 day MA, and that there is
Read More
Shares in drug development company Actinogen Medical (ASX: ACW) have plummeted following the results release of their Phase 2a clinical trial seeking a treatment for depression which has failed to meet its primary endpoint. In our fast-paced world, balancing a busy work schedule with life’s inevitable ups and downs can be challenging. Drugs for cognitive
Read More
In a bold move to flex muscles, Bailador Technology (ASX: BTI) has invested $7.7 million in Hapana Holdings, a software platform that promises to make gyms and fitness studios as efficient as a Swiss watch—or at least, that’s the idea. Hapana offers an all-encompassing software solution for gyms and boutique fitness studios, enabling them to
Read More
The XJO is expected to open higher this morning, near 7,850 at time of writing. The U.S finished slightly higher on Friday night, giving our market confidence to extend Friday’s gains. We are clearly bouncing off key support at 7,650, and should face resistance on open from the key level at 7,850, but also the
Read More
Luxury furniture retailer Nick Scali (ASX: NCK) has faced a challenging year, marked by declining revenue but is making strikes in its expansion efforts in its bid to strengthen their position in the high-end furniture market. The Company made strides post-acquisition of Fabb Furniture, particularly in its UK growth strategy. Rodney Orrock, formerly the CEO
Read More
A long-running legal dispute involving pharmaceuticals distribution company PharmX Technologies (ASX: PHX) has finally come to an end, and not in favour of shareholders with the Company ordered to pay $8.1 million in damages, interest and legal costs to Fred IT Group Pty Ltd. The Victorian Supreme Court’s Court of Appeal delivered its ruling, resulting
Read More
Myer Holdings (ASX: MYR) a long-established name in the retail industry, is navigating the stormy seas of a challenging market with docility. As consumers tighten their belts and inflationary pressures mount, Myer’s latest trading update addresses both the hurdles faced and the Company’s keen measures to secure a stable future. In June 2024, Myer made
Read More
In a blow to the Australian tech industry, audio tech company Nuheara (ASX: NUH) has entered voluntary administration after failing to renegotiate its debt obligations. This decision comes after a protracted strategic review aimed at rescuing the Company, which has ultimately failed. The primary issue revolves around a $2.5 million convertible note held by Realtek
Read More
